Immunoglobulin substitution therapy in patients with primary immunodeficiency
Authors:
P. Králíčková; I. Krčmová; J. Krejsek
Authors‘ workplace:
Přednosta: prof. RNDr. Jan Krejsek, CSc.
; Lékařská fakulta a Fakultní nemocnice v Hradci Králové
; ÚSTAV KLINICKÉ IMUNOLOGIE A ALERGOLOGIE
; Univerzita Karlova v Praze
Published in:
Prakt. Lék. 2014; 94(1): 10-15
Category:
Reviews
Overview
Immunoglobulin supplementation therapy represents a corner stone in the treatment of patients with disturbance of specific antibody production, which are sensitive to infectious diseases, mainly of bacterial origin. Specific treatment, way of administration, dosage and substitution interval is highly individual. The correctly guided treatment leads to significant decrease in the frequency of severe respiratory infections and probably also to deceleration of chronic changes in lung parenchyma. Numerous modulatory effects of substituted immunoglobulins on immunity and inflammatory response are proved. Nowadays the subcutaneous route of administration is often preferred to intravenous one. Either pumps ordirect rapid push method are used for immunoglobulin administration. Both methods of administration are comparable regarding their efficacy. Better comfort for patients is achieved with subcutaneous supplementation in their homes with low frequency of side effects in addition. The adverse events are only local and mild.
Keywords:
primary immunodeficiency – substitution – immunoglobulins
Sources
1. Abolhassani H, Sadaghiani MS, Aghamohammadi A, et al. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis. J Clin Immunol 2012; 32(6): 1180–1192.
2. Baris S, Ercan H, Cagan HH, et al. Efficacy of intravenous immunoglobulin treatment in children with common variable immunodeficiency. J Investig Allergol Clin Immunol 2011; 21(7): 514–521.
3. Bayary J, Dasgupta S, Misra N, et al. Intravenous immunoglobulin in autoimmune disorders: an insight into the immunoregulatory mechanisms. Int Immunopharmacol 2006; 6(4): 528–534.
4. Berger M. L-proline-stabilized human IgG: Privigen(R) 10% for intravenous use and Hizentra(R) 20 % for subcutaneous use. Immunotherapy 2011; 3(2): 163–176.
5. Bookbinder LH, Hofer A, Haller MF, et al. A recombinant human enzyme for enhanced interstitial transport of therapeutics. J Control Release 2006; 114(2): 230–241.
6. Bruton, OC, Apt L, Gitlin D, Janeway CA. Absence of serum gamma globulins. AMA Am J Dis Child 1952; 84(5): 632–636.
7. Cavaliere FM, Milito C, Martini H, et al. Quantification of IgM and IgA anti-pneumococcal capsular polysaccharides by a new ELISA assay: a valuable diagnostic and prognostic tool for common variable immunodeficiency. J Clin Immunol 2013; 33(4): 838–846.
8. de Gracia J, Vendrell M, Alvarez A, et al. Immunoglobulin therapy to control lung damage in patients with common variable immunodeficiency. Int Immunopharmacol 2004; 4(6): 745–753.
9. Eijkhout HW, van Der Meer JW, Kallenberg CG, et al. The effect of two different dosage of intravenous immunoglobulins on the incidence of recurrent infections in patients with primary hypogammaglobulinaemia – a randomized, double-blind, multicenter crossover trial. Ann Internal Med 2001; 135(3): 165–174.
10. Elluru SR, Vani J, Delignat S, et al. Modulation of human dendritic cell maturation and function by natural IgG antibodies. Autoimmun Rev 2008; 7(6): 487–490.
11. Elovaara I, Apostolski S, Van Doorn P, et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol 2008; 15(9): 893–908.
12. FDA Blood Products Advisory Commitee 62nd Meeting, Bethesda, Maryland, March 26, 1999. Transcript, Miller Reporting Company, Inc. [on-line]. Dostupné na: http://www.fda.gov/ohrms/docket(ac/99/transcpt/3504t2.pdf).
13. Gardulf A, Hammarstroem L, Smith CI. Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet 1991; 338(8760): 162–166.
14. Goldacker S, Draeger R, Warnatz K, et al. Active vaccination in patients with common variable immunodeficiency (CVID). Clin Immunol 2007; 124(3): 294–303.
15. Hagan JB, Fasano HB, Spector S, et al. Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency. J Clin Immunol 2010; 30(5): 734–745.
16. Hansen S, Gustafson R, Smith CI, Gardulf A. Express subcutaneous IgG infusions: decreased time of delivery with maintained safety. Clin Immunol 2002; 104(3): 237–241.
17. Horn J, Thon V, Bartonkova D, Salzer U, et al. Anti-IgA antibodies in common variable immunodeficiency (CVID): diagnostic workup and therapeutic strategy. Clin Immunol 2007; 122(2): 156–162.
18. Jolles S, Sleasman JW. Subcutaneous immunoglobulin replacement therapy with Hizentra, the first 20% SCIG preparation: a practical approach. Adv Ther 2011; 28(7): 521–533.
19. Kasztalska K, Ciebiada M, Cebula-Obrzut B, Górski P. Intravenous immunoglobulin replacement therapy in the treatment of patients with common variable immunodeficiency disease: an open-label prospective study. Clin Drug Investig 2011; 31(5): 299–307.
20. Krejsek J, Kopecký O. Klinická imunologie. Hradec Králové: Nucleus 2004.
21. Lucas M, Lee M, Lortan J, et al. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol 2010; 125(6): 1354–1360.
22. Nicolay U, Haag S, Eichman F, Herget S, et al. Measuring treatment satisfaction in patients with primary immunodeficiency diseases receiving lifelong immunoglobulin replacement therapy. Qual Life Res 2005; 14(7): 1683–1691.
23. Orange JS, Belohradsky BH, Berger M, et al. Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy. Clin Exp Immunol 2012; 169(2): 172–181.
24. Orange JS, Grossmann WJ, Navickis RJ, Wilker MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies. Clin Immunol 2010; 137(3): 21–30.
25. Quinti I, Soresina A, Agostini C, et al. Prospective study on CVID patients with adverse reactions to intravenous or subcutaneous IgG administration. J Clin Immunol 2008; 28(3): 263–267.
26. Quinti I, Soresina A, Guerra A, et al. Effectiveness of immunoglobulin replacemnt therapy on clinical outcome in patients with primary antibody deficiencies: results from a muticenter prospective cohort study. J Clin Immunol 2011; 31(3): 315–322.
27. Rezaei N, Aghamohammadi A, Siadat SD, et al. Serum bactericidal antibody responses to meningococcal polysaccharide vaccination as a basis for clinical classification of common variable immunodeficiency. Clin Vaccine Immunol 2008; 15(4): 607–611.
28. Shapiro RS. Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: a retrospective analysis. J Clin Immunol 2010; 30(4): 301–307.
29. Shapiro RS. Subcutaneous immunoglobulin: rapid push vs. infusion pump in pediatrics. Pediatr Allergy Immunol 2013; 24(1): 49–53.
30. Shapiro RS. Why I Use Subcutaneous Immunoglobulin (SCIG). J Clin Immunol 2013; 33(2): 95–98.
31. Siedlar M, Strach M, Bukowska-Strachova K, et al. Preparations of intravenous immunoglobulins diminish the number and proinflammatory response of CD14+CD16++ monocytes in common variable immunodeficiency (CVID) patients. Clin Immunol 2011; 139(2): 122–132.
32. Thepot S, Malphettes M, Gardeur A, et al. Immunoglobulin dosage and switch from intravenous to subcutaneous immunoglobulin replacement therapy in patients with primary hypogammaglobulinemia: decreasing dosage does not alter serum IgG levels. J Clin Immunol 2010; 30(4): 602–606.
33. Thomas JR, Yocum RC, Haller MF, von Gunten CF. Assessing the role of human recombinant hyaluronidase in gravity-driven subcutaneous hydration: the INFUSE-LR study. J Palliat Med 2007; 10(6): 1312–1320.
34. Torgerson TR, Bonagura VR, Shapiro RS. Clinical ambiguities-ongoing questions. J Clin Immunol 2013; 33(2): 99–103.
35. Wasserman R, Melamed I, Kobrynski L, et al. Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency disease. J Clin Immunol 2011; 31(3): 323–331.
36. Wasserman RL, Melamed I, Stein MR. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J Allergy Clin Immunol 2012; 130(4): 951–957.
Labels
General practitioner for children and adolescents General practitioner for adultsArticle was published in
General Practitioner
2014 Issue 1
Most read in this issue
- Paediatric trigger finger
- Problems in quality of life assessment in seniors
- Concept of the branch of General Practice
- Immunoglobulin substitution therapy in patients with primary immunodeficiency